Conatus Pharmaceuticals (Nasdaq: CNAT) 24.6% HIGHER; announced that it will report top-line results from three clinical trials in subjects with varying degrees of organ impairment – the company’s Phase 2 trial in patients with acute-on-chronic liver failure (ACLF), Phase 1 trial in patients with mild, moderate and severe hepatic impairment, and Phase 1 trial in patients with severe renal impairment – after the market close on Thursday, January 8, 2015. Conatus will